Indication
Recurrent Childhood Rhabdomyosarcoma
3 clinical trials
12 products
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolStatus: Recruiting, Estimated PCD: 2027-09-30
Product
EnsartinibProduct
ErdafitinibProduct
LarotrectinibProduct
OlaparibProduct
PalbociclibProduct
SamotolisibProduct
SelpercatinibProduct
SelumetinibProduct
TazemetostatProduct
TipifarnibProduct
UlixertinibProduct
VemurafenibClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair GenesStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 AlterationsStatus: Active (not recruiting), Estimated PCD: 2023-09-30